MLV Reiterates Upbeat View Of Dynavax Technologies Following DSMB’s 2nd Recommendation
MLV’s healthcare analyst Vernon Bernardino came out with a few insights on Dynavax Technologies Corporation (NASDAQ:DVAX), after the company’s independent Data and Safety Monitoring Board (DSMB) has completed a second pre-specified review of HBV-23, an ongoing Ph 3 trial of the company’s investigational adult hepatitis B vaccine, HEPLISAV-B, and recommended that HBV-23 continue unchanged.
Bernardino noted, “We believe the news continues to support our bullish view for confirmation of HEPLISAV -B’s safety, as the second DSMB review included unblinded safety data tables for all enrolled subjects, collected through the data cut-off in February. All subjects had received the last active dose of HEPLISAV-B and reached at least five months (i.e., ~23 weeks) follow-up. With the DSMB’s recommendation and final review of HBV-23 expected to be completed by October 2015 (one-year followup from post-September 2014 completion of enrollment), we look for completion of the study to result in positive confirmation of HEPLISAV-B’s safety in the entire 5,500-patient arm of HBV-23.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Vernon Bernardino has a total average return of -11.0% and a 33.3% success rate. Bernardino has a 5.8% average return when recommending DVAX, and is ranked #3407 out of 3497 analysts.